Clinical investigation of TROP-2 as an independent biomarker and potential therapeutic target in colon cancer
Abstract
Colon cancer is associated with a severe demographic and economic burden worldwide. The pathogenesis of colon cancer is highly complex and involves sequential genetic and epigenetic mechanisms. Despite extensive investigation, the pathogenesis of colon cancer remains to be elucidated. As the third most common type of cancer worldwide, the treatment options for colon cancer are currently limited. Human trophoblast cell‑surface marker (TROP‑2), is a cell‑surface transmembrane glycoprotein overexpressed by several types of epithelial carcinoma. In addition, TROP‑2 has been demonstrated to be associated with tumorigenesis and invasiveness in solid types of tumor. The aim of the present study was to investigate the protein expression of TROP‑2 in colon cancer tissues, and further explore the association between the expression of TROP‑2 and clinicopathological features of patients with colon cancer. The expression and localization of the TROP‑2 protein was examined using western blot analysis and immunofluorescence staining. Finally, the expression of TROP‑2 expression was correlated to conventional clinicopathological features of colon cancer using a χ2 test. The results revealed that TROP‑2 protein was expressed at high levels in the colon cancer tissues, which was associated with the development and pathological process of colon cancer. Therefore, TROP‑2 may be used as a biomarker to determine the clinical prognosis, and as a potential therapeutic target in colon cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TROP2 is frequently upregulated in colorectal cancer and serves as a negative prognostic marker.
“the glycoprotein TROP2,81 originally described as a surface marker of the embryonal trophoblast,82 is frequently upregulated in CRC and serves as a negative prognostic marker.83”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 31 · Cited by 24
- Authors
- ZHAO, P., YU, H.-Z., & CAI, J.-H.
- Affiliations
- Hebei Medical University (CN)
- North China University of Science and Technology (CN)
- ORCID
- ZHAO, PENG
- Venue
- Molecular Medicine Reports
- Publisher
- Spandidos Publications
- Published
- 2015-06-08
- Volume
- 12
- Issue
- 3
- Pages
- 4364-4369
- ISSN
- 1791-2997 (ISSN-L)
- 1791-3004
- OpenAlex
- W2153975697
- Cited by
- 24
- References
- 31
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 5 · 2017: 3
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Medicine Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- TROP2, colon cancer, biomarkers, therapeutic target, protein expression, clinicopathological features, prognosis, tumor invasion, epithelial cancers
- MeSH terms
- Adenocarcinoma, Antigens, Neoplasm, Colon, Colonic Neoplasms, Female, Humans, Lymphatic Metastasis, Male, Middle Aged, Biomarkers, Tumor, Cell Adhesion Molecules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
